These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 4996249)

  • 1. [Comparative study of the development of rifomycin blood levels in humans by 2 different microbiologic methods].
    Canetti G; Djurovic V; Le Lirzin M; Thibier R; Lepeuple A
    Rev Tuberc Pneumol (Paris); 1970; 34(1):93-106. PubMed ID: 4996249
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study of tuberculostatic activity and blood concentration of new agents--rifampicin and ethambutol--in patients with pulmonary tuberculosis].
    Mkrtchian SV; Ushkin VV
    Antibiotiki; 1971 May; 16(5):472-7. PubMed ID: 5002224
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes in the bacteriologic findings in patients treated with rifomycin, alone or associated with other drugs].
    Delli Veneri F; Centrella G; Stefanelli R
    Arch Tisiol Mal Appar Respir; 1968 May; 23(5):387-98. PubMed ID: 4979475
    [No Abstract]   [Full Text] [Related]  

  • 4. [Incidence and significance of positive fluorescent bacilloscopy associated with negative cultures during treatment based on isoniazid or rifomycin in tubercular patients treated in the sanatorium].
    Augier J; Parrot R; Gillet P
    Acta Tuberc Pneumol Belg; 1969; 60(3):417-29. PubMed ID: 4984422
    [No Abstract]   [Full Text] [Related]  

  • 5. [Rifamicin in the studies of the Scuola Tisiologica in Naples].
    Nitti V
    Arch Tisiol Mal Appar Respir; 1968 Apr; 23(4):271-92. PubMed ID: 4981409
    [No Abstract]   [Full Text] [Related]  

  • 6. [Determination of drug resistance of Mycobacterium tuberculosis by methods of proportions and absolute concentrations].
    Golyshevskaia VI; Sevast'ianova EV; Voronina GA
    Probl Tuberk; 2001; (3):51-3. PubMed ID: 11508236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survival of tuberculous bacilli in combined treatments including rifampicin].
    Kreis B; Pretet S
    Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bacteriologic negation and anatomic development in pulmonary specimens after rifampicin treatment of less than 10 months (10 cases)].
    Constans P; Parrot R; Coury C
    Rev Tuberc Pneumol (Paris); 1970 Jun; 34(4):511-8. PubMed ID: 4994883
    [No Abstract]   [Full Text] [Related]  

  • 9. [The characteristics of the sensitivity of Mycobacterium tuberculosis to rifampicin and isoniazid through determination of mutations in the genes rpoB, katG, inhA, oxyR, and kasA by different molecular biological assays].
    Skotnikova OI; Galkina KIu; Nosova EIu; Krasnova MA; Moroz AM
    Probl Tuberk Bolezn Legk; 2005; (8):42-5. PubMed ID: 16209020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin.
    Jenne JW; Beggs WH
    Am Rev Respir Dis; 1973 Jun; 107(6):1013-21. PubMed ID: 4197230
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of recent pulmonary tuberculosis with combined rifomycin-isoniazid].
    Constans P; Morin Y; Coury C; Bariety M
    Acta Tuberc Pneumol Belg; 1969; 60(3):545-53. PubMed ID: 5371679
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anti-mycobacterial activity of rifampicin].
    Gialdroni Grassi G
    G Ital Mal Torace; 1971; 25(2):77-88. PubMed ID: 5003253
    [No Abstract]   [Full Text] [Related]  

  • 13. The method of vertical diffusion for the determination of drug sensitivity of Mycobacterium tuberculosis and the concentration of biologically active tubazid in the blood serum of patients with tuberculosis.
    Gelberg SI; Kulgovenya PS
    J Hyg Epidemiol Microbiol Immunol; 1972; 16(4):447-56. PubMed ID: 4629404
    [No Abstract]   [Full Text] [Related]  

  • 14. Experimental and clinical studies of rifampicin in tuberculosis.
    Konno K; Oizumi K; Hayashi I; Oka S
    Sci Rep Res Inst Tohoku Univ Med; 1970 Dec; 17(3):110-20. PubMed ID: 5004309
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 16. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-course treatment regimens for patients with tuberculosis.
    Dutt AK; Stead WW
    Arch Intern Med; 1980 Jun; 140(6):827-9. PubMed ID: 6770770
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
    Toungoussova S; Caugant DA; Sandven P; Mariandyshev AO; Bjune G
    Int J Tuberc Lung Dis; 2002 May; 6(5):406-14. PubMed ID: 12019916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reasons for drug-resistant tuberculosis emergence].
    Tu DH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):403-5. PubMed ID: 17673006
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative therapeutic activity of rifampicin and isoniazid in different densities of microbial population in the lungs of experimental animals].
    Sodikov ES; Ismatullaev F
    Probl Tuberk; 1986; (6):50-3. PubMed ID: 3092209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.